Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation

Background: Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission....

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho, Franceli Ramos, Zuckermann, Joice, Paz, Alessandra, Fischer, Gustavo, Daudt, Liane Esteves, Rigoni, Lisandra Della Costa, Silla, Lúcia, Fogliatto, Laura, de Castro, Simone Martins, Pilger, Diogo André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338279/
https://www.ncbi.nlm.nih.gov/pubmed/28286612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338279/
https://www.ncbi.nlm.nih.gov/pubmed/28286612

Ejemplares similares